Zafari, Z., Sadatsafavi, M., & Mark FitzGerald, J. (2018). Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc.
Citação norma ChicagoZafari, Zafar, Mohsen Sadatsafavi, and J. Mark FitzGerald. "Cost-effectiveness of Tiotropium Versus Omalizumab for Uncontrolled Allergic Asthma in US." Cost Eff Resour Alloc 2018.
MLA引文Zafari, Zafar, Mohsen Sadatsafavi, and J. Mark FitzGerald. "Cost-effectiveness of Tiotropium Versus Omalizumab for Uncontrolled Allergic Asthma in US." Cost Eff Resour Alloc 2018.
警告：這些引文格式不一定是100％准確.